Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth "GLP-1 agonist" for diabetes...joining Bydureon, Byetta, Tanzeum, Trulicity, and Victoza.

Expect to see more than one Rx for patients starting on Adlyxin. Most patients will use the Starter Pack for one month...then switch to the Maintenance Pack long-term. Each pack will cost about $550.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote